,zip,sector,fullTimeEmployees,longBusinessSummary,city,phone,state,country,companyOfficers,website,maxAge,address1,fax,industry,address2,ebitdaMargins,profitMargins,grossMargins,operatingCashflow,revenueGrowth,operatingMargins,ebitda,targetLowPrice,recommendationKey,grossProfits,freeCashflow,targetMedianPrice,currentPrice,earningsGrowth,currentRatio,returnOnAssets,numberOfAnalystOpinions,targetMeanPrice,debtToEquity,returnOnEquity,targetHighPrice,totalCash,totalDebt,totalRevenue,totalCashPerShare,financialCurrency,revenuePerShare,quickRatio,recommendationMean,exchange,shortName,longName,exchangeTimezoneName,exchangeTimezoneShortName,isEsgPopulated,gmtOffSetMilliseconds,quoteType,symbol,messageBoardId,market,annualHoldingsTurnover,enterpriseToRevenue,beta3Year,enterpriseToEbitda,52WeekChange,morningStarRiskRating,forwardEps,revenueQuarterlyGrowth,sharesOutstanding,fundInceptionDate,annualReportExpenseRatio,totalAssets,bookValue,sharesShort,sharesPercentSharesOut,fundFamily,lastFiscalYearEnd,heldPercentInstitutions,netIncomeToCommon,trailingEps,lastDividendValue,SandP52WeekChange,priceToBook,heldPercentInsiders,nextFiscalYearEnd,yield,mostRecentQuarter,shortRatio,sharesShortPreviousMonthDate,floatShares,beta,enterpriseValue,priceHint,threeYearAverageReturn,lastSplitDate,lastSplitFactor,legalType,lastDividendDate,morningStarOverallRating,earningsQuarterlyGrowth,priceToSalesTrailing12Months,dateShortInterest,pegRatio,ytdReturn,forwardPE,lastCapGain,shortPercentOfFloat,sharesShortPriorMonth,impliedSharesOutstanding,category,fiveYearAverageReturn,previousClose,regularMarketOpen,twoHundredDayAverage,trailingAnnualDividendYield,payoutRatio,volume24Hr,regularMarketDayHigh,navPrice,averageDailyVolume10Day,regularMarketPreviousClose,fiftyDayAverage,trailingAnnualDividendRate,open,toCurrency,averageVolume10days,expireDate,algorithm,dividendRate,exDividendDate,circulatingSupply,startDate,regularMarketDayLow,currency,regularMarketVolume,lastMarket,maxSupply,openInterest,marketCap,volumeAllCurrencies,strikePrice,averageVolume,dayLow,ask,askSize,volume,fiftyTwoWeekHigh,fromCurrency,fiveYearAvgDividendYield,fiftyTwoWeekLow,bid,tradeable,dividendYield,bidSize,dayHigh,regularMarketPrice,preMarketPrice,logo_url
0,10014,Healthcare,365,"TG Therapeutics, Inc., a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell malignancies and autoimmune diseases. Its therapeutic product candidates include Ublituximab, an investigational glycoengineered monoclonal antibody for the treatment of B-cell non-hodgkin lymphoma, chronic lymphocytic leukemia (CLL), and relapsing forms of multiple sclerosis; and Umbralisib, an oral inhibitor of PI3K-delta and CK1-epsilon for the treatment of CLL, marginal zone lymphoma, and follicular lymphoma. The company also develops Cosibelimab, a human monoclonal antibody of IgG1 subtype that binds to programmed death-ligand 1 (PD-L1) and blocks its interactions with PD-1 and B7.1 receptors; TG-1701 is an orally available and covalently-bound Bruton's tyrosine kinase (BTK) inhibitor that exhibits selectivity to BTK compared to ibrutinib in in vitro kinase screening; and TG-1801, a bispecific CD47 and CD19 antibody. In addition, it has various licensed preclinical programs for BET, interleukin-1 receptor associated kinase-4, and GITR; and collaboration agreements with Checkpoint Therapeutics, Inc., Jiangsu Hengrui Medicine Co., Novimmune SA, Ligand Pharmaceuticals Incorporated, and Jubilant Biosys. The company has strategic alliances with LFB Biotechnologies S.A.S; GTC Biotherapeutics; LFB/GTC LLC; Ildong Pharmaceutical Co. Ltd.; and Rhizen Pharmaceuticals, S A. The company is headquartered in New York, New York.",New York,212 554 4484,NY,United States,[],http://www.tgtherapeutics.com,1,2 Gansevoort Street,212 554 4531,Biotechnology,9th Floor,0,0,0.86836,-260751008,52.421,-76.85089,-338350016,26,buy,152000,-134101376,57.5,24.41,,4.241,-0.61921,8,58.38,9.024,-1.4226401,84,356849984,28110000,4406000,2.725,USD,0.034,4.087,2,NCM,"TG Therapeutics, Inc.","TG Therapeutics, Inc.",America/New_York,EST,False,-18000000,EQUITY,TGTX,finmb_143627354,us_market,,650.876,,-8.476,-0.18876702,,-2.36,,142943008,,,,2.379,13457143,0.0942,,1609372800,0.72223,-342980992,-2.636,,0.31316328,10.260613,0.07359,1672444800,,1632960000,19.4,1632960000,120376151,1.762597,2867759104,2,,1335744000,100:5625,,,,,791.9289,1635465600,,,-10.343221,,0.1179,13523063,,,,24.86,24.7,36.58085,,0,,25.18,,1501360,24.86,31.7234,,24.7,,1501360,,,,,,,24.2,USD,1339793,,,,3489238784,,,1201843,24.2,24.59,800,1339793,56.74,,,21.058,24.15,False,,900,25.18,24.41,,https://logo.clearbit.com/tgtherapeutics.com
